RESEARCH ARTICLE

The Factors Related to CD4+ T-Cell Recovery and Viral Suppression in Patients Who Have Low CD4+ T Cell Counts at the Initiation of HAART: A Retrospective Study of the National HIV Treatment Sub-Database of Zhejiang Province, China, 2014

Lin He1, Xiaohong Pan1*, Zhihui Dou2, Peng Huang3, Xin Zhou1, Zhihang Peng3, Jinlei Zheng1, Jiafeng Zhang1, Jiezhe Yang1, Yun Xu1, Jun Jiang1, Lin Chen1, Jianmin Jiang1, Ning Wang2*

1 Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, Zhejiang, China, 2 National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China, 3 Department of Epidemiology & Biostatics, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu, China

* xhpan@cdc.zj.cn (XP); wangnbj@163.com (NW)

Abstract

Background

Since China has a unique system of delivering HIV care that includes all patients’ records. The factors related to CD4+ T-cell recovery and viral suppression in patients who have low CD4+ T cell counts at the initiation of HAART are understudied in the China despite subsequent virological suppression (viral load < 50 copies/mL) is unknown.

Methods

The authors conducted a retrospective cohort study using data from the national HIV treatment sub-database of Zhejiang province to identify records of HIV+ patients. Patient records were included if they were ≥ 16 years of age, had an initial CD4 count < 100 cells/μL, were on continuous HAART for at least one year by the end of December 31, 2014; and achieved and maintained continued maximum virological suppression (MVS) (< 50 copies/ml) by 9 months after starting HAART. The primary endpoint for analysis was time to first CD4+ T cell count recovery (≥ 200, 350, 500 cells/μL). Cox proportional hazard regression was used to identify the risk factors for CD4+ T cell count recovery to key thresholds (200–350, 350–500, ≥ 500 cells/μL) by the time of last clinical follow-up (whichever occurred first), key thresholds (follow-up date for analysis), with patients still unable to reach the endpoints being censored by the end December 31, 2014 (follow-up date for analysis).
Results

Of the 918 patients who were included in the study, and the median CD4+ T cell count was 39 cells/μL at the baseline. At the end of follow-up, 727 (79.2%), 363 (39.5%) and 149 (16.2%) patients had return to ≥ 200, 350, and 500 cells/μL, respectively. Kaplan-Meier analysis demonstrated that the rate of patients with CD4+ count recovery to ≥ 200, 350, and 500 cells/μL after 1 year on HAART was 43.6, 8.6, and 2.5%, respectively, after 3 years on treatment was 90.8, 46.3, and 17.9%, respectively, and after 5 years on HAART was 97.1, 72.2, and 36.4%, respectively. The median time to return to 200–350, 350–500, ≥ 500 cells/μL was 1.11, 3.33 and 6.91 years, respectively. Factors of age (aHR = 0.77, 95% CI 0.61–0.97), baseline CD4+ count (aHR = 1.60, 95% CI 1.37–1.86), initial regimens, changes in regimen (aHR = 0.58, 95% CI 0.49–0.69), and inclusion of a cotrimoxazole prophylaxis (aHR = 0.66, 95% CI 0.51–0.85) were associated with CD4+ T cell count recovery.

Conclusion

The proportion of patients with initially low CD4 counts after nine months of treatment and that achieved continuous virological suppression was greater than 70% for persons with CD4+ count ≥ 350. Conversely, only 35% of patients recovered to levels of 500 cells/μL after 5 years of treatment, and levels continued to rise significantly with further long-term HAART. Early HAART intervention will be necessary for achieving effective CD4+ T cell responses and optimal immunological function in HIV+ patients.

Introduction

Highly active antiretroviral therapy (HAART) has significantly reduced mortality rates in HIV-infected patients due to virological suppression and CD4+ T cell count recovery [1]. Reducing the HIV virus load (VL) to the undetectable levels is the main goal of HAART, according to the current WHO guidelines [2]. CD4+ T cell count is a major indicator of HIV infection disease progression [3]. Patients who receive a late diagnosis have significantly poorer responses to HAART and worse prognoses [4]. However, some patients do not achieve complete CD4 recovery even with long-term virological suppression after HAART [5]. Previous studies showed that factors including age, specific drug regimen, and initial CD4 count were associated with CD4 count recovery among patients with virological suppression [6,7,8]. A cohort study indicated that a low CD4 count before treatment was a risk factor for not achieving a CD4 > 200 cells/μL [5]. Few studies have examined CD4 recovery in the context of viral suppression for more than five years. The EuroSIDA study demonstrated that patients with lower CD4 count (< 200 cells/μL) had significant rise in CD4 count even after five years of viral suppression with HAART [9]. Patients with CD4+ T counts below 100 cells/μL at initiation of HAART had over a 90% chance of recovery to above 200 cells/μL after 3 years of HAART despite VL suppression. However, only 25% of patients recovered to 500 cells/μL [10]. According to long-term HAART studies, among patients with virological suppression, only those with baseline CD4 count > 350 cells/μL returned to the normal CD4 count after six years of treatment. Conversely, patients with a lower CD4 baseline count had incomplete recovery [11].

It is still not clear whether HIV patients with severely impaired immune function (CD4+ < 100 cells/μL) can return to any significant key thresholds (≥ 200, 350, 500 cells/μL) despite...
achieving a long-term continued MVL suppression (VL < 50 copies/mL) by of 9 months after starting HAART. The aim of this study was to describe CD4 count changes during HAART, and its associated factors affecting the CD4 count in complete recovery to the endpoints (≥ 200, 350, 500 cells/µL) while achieving and maintaining continuous MVL suppression (VL < 50 copies/mL) in patients with lower initial CD4+ baseline count prior to HAART in Zhejiang province, China.

In 2014, 103,501 people were diagnosed with HIV-infection in China [12], with forty percent of patients have presented with a late diagnosis of AIDS (CD4 count < 200 cells/µL) in China [13]. The proportion of late diagnoses is about 30% in Zhejiang province, China. Nearly half of patients have CD4+ counts less than 100 cells/µL. Each year had a greater number of newly diagnosed patients received HAART that were severely immunocompromised. Given that many patients who start HAART are severely immunocompromised, it is vital to study CD4+ T count recovery in order to modify the drug regimen or to implement more intensive follow-up as necessary. Our study focused on CD4+ T cell count recovery of patients who had initial CD4+ levels of < 100 cells/µL.

Materials and Methods

Database

Patients’ data were obtained from the national treatment sub-database of Zhejiang province. These included all patients who met the national treatment guidelines (CD4 count < 200 cells/µL before 2010, CD4 < 350 cells/µL from 2010 to 2014, and CD4 < 500 cells/µL in 2014) and were provided free drug treatment [14]. Patients received regular follow-up care after starting HAART. The local Centers for Disease Control or other health-care providers recorded details of treatment at baseline, at follow-up visits 0.5, 1, 2 and 3 months later and once every 3 months thereafter. The follow-up mainly included clinical evaluation and laboratory monitoring, such as CD4 testing, blood routine, liver function, and kidney function analysis. Free regular CD4 monitoring was provided every three months in the first year of treatment, and after that twice a year (the CD4 test conducted between 4 to 8 months after first year). VL testing was conducted once a year, the first VL conducted not less than 9 months after HAART, the interval between VL testing not less than 6 months after first VL testing. The local CDC or other health care organizations would complete a questionnaire after each follow-up. The above treatment database and follow-up have been described elsewhere [1,15].

Inclusion criteria

All patients who were ≥ 16 years before treatment, had an initial CD4 count < 100 cells/µL, and had received continuous treatment for at least one year by the end of December 31, 2014 were included in the study. Patient records were also included if they achieved and maintained continuous suppression by 9 months after starting HAART.

Exclusion criteria

Exclusion criteria were as follows: VL ≥ 50 copies/mL, if the VL detection had been interrupted (the VL testing was not conducted annually) during the treatment, and if there was loss of follow-up such as death or discontinuation of treatment. Two sensitive PCR techniques for measuring VL with the lower limit of detection of 50 copies/mL were used in Zhejiang province. Therefore, VL < 50 copies/ml was used as the maximum virological suppression in this study.
HAART Treatment

Seven drugs divided into three categories were provided in the National Free Antiretroviral treatment Programme. The initial HAART regimens included 2 nucleoside reverse-transcriptase inhibitors (NRTIs) and 1 non-nucleoside reverse-transcriptase inhibitor (NNRTI) or 1 protease inhibitor (PIs). The NRTIs consisted of Stavudine (D4T), Zidovudine (AZT), and Tenofovir (TDF), with Lamivudine (3TC), the NNRTIs included Nevirapine (NVP) and Efavirenz (EFV), the PIs was Lopinavir/r (LPV/r). TDF and LPV/r was as the secondary line drugs before 2013. In 2013, TDF could be used as the first line treatment drug according to the National Treatment Guidelines. Meanwhile owing to the side effect of treatment or drug toxicity, D4T is no longer used in China, and patients who took D4T changed to use AZT or TDF in 2013.

Statistical analysis

Descriptive statistics were calculated with the Student’s t test, One-Way ANOVA and the chi-square ($\chi^2$) test. Semi-annual changes in CD4 counts for five years after HAART to the end of December 31, 2014 were analyzed. The calculation process of CD4 count was that, for example, calculated the CD4 count in 6 months after treatment, the CD4 tested date between 4.5–7.5 months was collected, if the patient had more than one time of CD4 results in the period, the date of CD4 results closer to the 6 months was collected. We determined the mean CD4 (95% confidence interval, 95%CI) and median (interquartile, IQR) in the absolute CD4 count at baseline and semiannually thereafter.

The endpoint of the study was when CD4+ T counts first achieved key thresholds ($\geq$ 200, 350, 500 cells/$\mu$L) and were defined complete and successful CD4 recovery. Person-years were calculated from the date of starting HAART to the time of last follow-up, whichever occurred first ($\geq$ 200, 350, 500) key thresholds (follow-up date for analysis), with patients still unable to recovery the endpoints censored by the end December 31, 2014 (follow-up date for analysis). Kaplan-Meier plots were used to estimate the rates of CD4+ recovery to the thresholds. Cox proportional hazards regression were used to identify the factors associated with endpoints of CD4+ count recovery for participants in this study.

Univariate factors with $P < 0.1$ and factors previously shown to be associated with the CD4 + T cell count recovery after assessing collinearity and possible interactions were placed in full multivariable regression models, including age, gender, transmission route, presence of infection with Mycobacterium tuberculosis (TB) before treatment, initial CD4 count, WHO clinical stage, presence of change in regimen, and cotrimoxazole prophylaxis (TMP-SMZ) during the treatment and the initial regimen. Complete follow-up data were collected, which included every CD4 test results, HIV viral load measurements, and any changes in drug regimen.

All analyses were performed using STATA 12.1 (StataCorp LP, College Station, TX, USA).

Ethical Approval

This study was reviewed and approved by the Institutional Review Board of the National Center for AIDS/STD Control and Prevention, China CDC (IRB approval number: X120331209). All the data was obtained from the national HIV treatment sub-database of Zhejiang province. All the patients who received the national free treatment at baseline, the local CDC or health-care providers would inform patient that all the treatment information may be used for the monitoring analysis. All the patients signed the informed consent.

Results

A total of 918 patients were included in the study, and the total follow-up was 2722.1 person-years by the deadline of Dec 31, 2014, with an average 2.97 ± 1.74 years. The median treatment
time was 2.5 years (IQR 1.6–4.0 years), of which the shortest was 1.0 year and the longest was 9.5 years. The person-years of CD4+ count achieved the thresholds (200–350, 350–500, ≥500 cells/μL) were 0.99 years (IQR 0.50–1.57 years), 1.79 years (IQR 1.16–2.74 years), and 2.19 years (IQR 1.31–3.34 years). Fig 1 shows the study profile, while Table 1 depicts the demographic characteristics of patient records by the CD4+ T cell count recovery to the endpoints (≥200, 350, 500 cells/μL). The median age was 39 (IQR 31–47) years. The majority of the patients were male (82.4%), the major transmission route was heterosexual transmission (64.2%). Additionally, 6.6% patients had been infected with TB one year before starting HAART. The median CD4 count was 39 cells/μL (IQR 17–68 cells/μL) at initiation; over half (60.0%) of patients had CD4+ counts less than 50 cells/μL. Nearly half (43.1%) of the subjects were at the WHO clinical stage 1 before starting treatment. The initial treatment regimens were D4T/3TC/NVP (19.7%), D4T/3TC/EFV (19.5%), AZT/3TC/NVP (26.0%), and AZT/3TC/EFV (26.6%). During the follow-up period, 31.5%, 44.4%, and 51.1% of patients changed their initial treatment regimen and achieved the endpoints of ≥200, 350, and 500 cells/μL, respectively. Approximately 10.9%, 15.8%, and 16.1% of the patients had been on SMZ-TMP treatment for the respective thresholds.

**CD4+ T cell count recovery**

At the end of follow-up, 727 patients (79.2%) had returned to ≥200 cells/μL, 363 of patients (39.5%) had achieved greater than 350 cells/μL, and 149 patients (16.2%) returned to ≥500
As a result, the total rate of CD4+ count recovery thresholds ($\geq 200$, $350$, $500$ cells/$\mu$L) were 83.7/100 person-years, 47.8/100 person-years, and 39.3/100 person-years, respectively.

**Fig 2** shows the CD4+ count increased during the treatment from starting HAART to 5 years on treatment. Along with HAART duration, CD4+ count continually increased, even

### Table 1. Social demographic and characteristics of 918 patients, by the CD4+ T cell recovery to the endpoints ($\geq 200$, $350$, $500$ cells/$\mu$L).

| Characteristic | All patients | CD4+ count return to $\geq 200$ cells/$\mu$L | CD4+ count return to $\geq 350$ cells/$\mu$L | CD4+ count return to $\geq 500$ cells/$\mu$L |
|---------------|-------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|
| Duration of follow-up in years, median (IQR) | 0.99(0.50–1.57) | 1.79(1.16–2.74) | 2.19(1.31–3.34) |
| Number of scheduled follow-up visits, median (IQR) | 8(6–12) | 13(9–18) | 1 (11–22) |
| Age, median (IQR) years | 39(31–47) | 47(39–55) | 50(43–57) |
| Female | 162(17.6) | 116(12.9) | 140(15.4) |
| Transmission route | | | |
| Heterosexual | 589(64.2) | 402(47.7) | 349(39.5) |
| Homosexual | 284 (30.9) | 174(20.5) | 169(19.1) |
| Others | 45 (4.9) | 31 (3.9) | 19 (2.2) |
| Whether infected Tuberculosis in the prior year | | | |
| No | 857 (93.4) | 734(92.2) | 663(90.4) |
| Yes | 61 (6.6) | 9(1.2) | 15(1.9) |
| Baseline CD4 count (cells/$\mu$L) [median (IQR)] | | | |
| $< 50$ | 551 (60.0) | 486(61.3) | 421(51.9) |
| 50–99 | 367 (40.0) | 247(30.6) | 228(28.2) |
| WHO clinical stage | | | |
| 1 | 396(43.1) | 326(42.7) | 272(34.6) |
| 2 | 149(16.2) | 125(16.1) | 132(16.4) |
| 3 | 241(26.3) | 221(28.4) | 195(24.7) |
| 4 | 132 (14.4) | 115(15.0) | 114(14.4) |
| Initial regimens | | | |
| D4T+3TC+NVP | 181 (19.7) | 138(19.0) | 114(15.7) |
| D4T+3TC+EFV | 179 (19.5) | 141(17.9) | 115(16.2) |
| AZT+3TC+NVP | 239 (26.0) | 206(26.9) | 196(26.1) |
| AZT+3TC+EFV | 244 (26.6) | 217(28.5) | 197(26.1) |
| Others | 75 (8.2) | 58(7.5) | 57(7.3) |
| Changes in regimen | | | |
| No | 629(68.5) | 510(55.6) | 449(48.9) |
| Yes | 289(31.5) | 408(44.4) | 469(51.1) |
| Whether subjects took TMP-SMZ During the treatment | | | |
| No | 818(89.1) | 773(84.2) | 770(83.9) |
| Yes | 100(10.9) | 145(15.8) | 148(16.1) |

WHO: World Health Organization.

a All values in the table represent absolute numbers and percentages unless otherwise stated.

doi:10.1371/journal.pone.0148915.t001
long term after HAART initiation. The greatest CD4+ count rapid rise was seen in the first year after receiving treatment; the median CD4+ count was 39 cells/μL at baseline, up to 143 cells/μL at 0.5 year, 185 cells/μL at 1.0 year. The median CD4+ count increased slowly after that, reaching 262 cells/μL at year 2, 299 cells/μL at year 3, 331 cells/μL at year 4, and 361 cells/μL at year 5.

Fig 3 shows the Kaplan-Meier plots of the CD4+ count recovery to the endpoints (≥200, 350, 500 cells/μL) from the time starting treatment. Kaplan-Meier estimates that the rate of patients CD4+ count recovery to less than 200–350, 350–500, ≥500 cells/μL after 1 year on HAART was 43.6%, 8.6%, 2.5%, respectively, the proportion that returned to these endpoints after 3 years of treatment was 90.8%, 46.3%, 17.9%, respectively, and the proportion that recovered to these thresholds after 5 years on HAART was 97.1%, 72.2%, 36.4%, respectively. The plots indicate that the median time to return to ≥200, 350, 500 cells/μL was 1.11, 3.33 and 6.91 years, respectively.

Univariate Cox regression models analysis found that the factors of greater age and baseline CD4+ count (hazard ratio, HR: 1.60) were associated with the CD4+ count recovery to ≥200 cells/μL. Among patients who used first line drugs as the initial treatment regimen, the use of the AZT compared to D4T, of EFV compared to NVP, of changing regimen, (HR: 0.58, Table 2) and of taking TMP-SMZ during treatment (HR: 0.61) were positively associated with CD4+ count recovery to ≥200 cells/μL. Multivariate Cox regression analysis showed that these associations remained significant after adjusting for all potential confounders.
The factors associated with the CD4+ T cell recovery

Univariate analysis found that the factors of CD4+ count recovery to $\geq 350$ cells/$\mu$L consistent with the factor of CD4+ count return to $\geq 350$, cells/$\mu$L, except for the factor of baseline CD4+ count. These associated factors remained significant in the multivariate analysis.

Factors correlated with CD4+ counts returning to $\geq 500$ cells/$\mu$L were analyzed by univariate Cox regression models. The initial regimens containing AZT compared to D4T, and EFV compared to NVP were positively related to CD4+ count recovery. Among patients who switched regimens, our analysis demonstrated that they were more likely to reach a CD4 count of $\geq 500$. These correlations remained significant after adjustment in the multivariate analysis.

Discussion

This is the first report that examines HIV patients CD4+ T cell count recovery to significant thresholds ($\geq 200, 350, 500$ cells/$\mu$L) in China with lower CD4 counts at the start of the initial HAART treatment despite achieving continuous MVL suppression. Records from the national database showed that 727 (79.2%), 363 (39.5%) and 149 (16.2%) of patients had recovery to defined endpoints ($\geq 200, 350, 500$ cells/$\mu$L). The total proportion of CD4+ count recovery to the thresholds were 83.7/100 person-years, 47.8/100 person-years, and 39.3/100 person-years, respectively. The CD4+ count of the majority of patients was significantly increased after treatment, even at 5 years. Specifically, rapid increase was seen in the first year of treatment, while the increases in 2–5 years were gradual. Previous studies revealed that HIV+ patients with high CD4+ initial count ($\geq 350$ cells/$\mu$L) could have complete recovery to either HIV-negative or normal levels. However, the corresponding recovery would be lower in patients with initial
Table 2. Rate of CD4+ T cell count recovery to the endpoints (≥ 200, 350, 500 cells/µL) and its associated factors.

| Factor                       | CD4+ count recovery to ≥ 200 cells/µL | CD4+ count recovery to ≥ 350 cells/µL | CD4+ count recovery to ≥ 500 cells/µL |
|------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|
|                              | Rate % n/N Unadjusted HR (95% CI)     | Rate % n/N Unadjusted HR (95% CI)     | Rate % n/N Unadjusted HR (95% CI)     |
| Age, years                   |                                      |                                      |                                      |
| < 30                         | 85.5(171/200) 1.0                     | 46.5(93/200) 1.0                     | 19.5(39/200) 1.0                     |
| 30–                          | 83.6(240/287) 0.90(0.74–1.10)         | 46.0(132/287) 0.86(0.66–1.12)        | 20.9(60/287) 0.94(0.63–1.40)        |
| 40–                          | 74.4(183/246) 0.71(0.58–0.88)         | 33.3(82/246) 0.64(0.48–0.86)         | 13.0(32/246) 0.68(0.43–1.09)        |
| 50–                          | 71.9(133/185) 0.70(0.56–0.88)         | 30.3(56/185) 0.58(0.41–0.81)         | 9.7(18/185) 0.52(0.30–0.91)         |
| Baseline CD4 count (cells/µL)|                                      |                                      |                                      |
| < 50                         | 75.9(418/551) 1.63(1.41–1.89)         | 41.1(151/367) 1.20(0.97–1.48)        | 15.5(57/367) 1.02(0.73–1.41)        |
| 50–99                        | 84.2(309/367) 1.60(1.37–1.86)         | 41.6(132/287) 1.20(0.97–1.48)        | 20.9(60/287) 0.94(0.63–1.40)        |
| Initial regimens             |                                      |                                      |                                      |
| D4T+3TC+NVP                  | 95.0(172/181) 1.0                     | 61.9(112/181) 1.0                     | 27.1(49/181) 1.0                     |
| D4T+3TC+EFV                  | 79.9(143/179) 0.82(0.65–1.02)         | 44.7(80/179) 0.90(0.68–1.20)         | 19.0(34/179) 1.04(0.67/1.62)        |
| AZT+3TC+NVP                  | 78.2(187/239) 0.81(0.66–0.99)         | 31.4(75/239) 0.63(0.47–0.84)         | 10.9(26/239) 0.64(0.40/1.04)        |
| AZT+3TC+EFV                  | 70.9(173/244) 0.77(0.62–0.95)         | 33.2(81/244) 0.87(0.65–1.17)         | 11.9(29/244) 0.91(0.57/1.46)        |
| Others                       | 69.3(52/75) 1.03(0.75–1.40)           | 20.0(15/75) 0.89(0.52–1.53)          | 14.7(11/75) 1.92(0.99/3.72)         |
| Changes in regimen           |                                      |                                      |                                      |
| No                           | 84.7(533/629) 1.0                     | 47.8(244/510) 1.0                     | 24.3(109/449) 1.0                     |
| Yes                          | 67.1(194/289) 0.57(0.40–0.67)         | 29.2(119/408) 0.44(0.35–0.54)        | 8.5(40/469) 0.25(0.17–0.35)         |
| Whether took TMP–SMZ During the treatment |                                      |                                      |                                      |
| No                           | 80.6(659/818) 1.0                     | 41.7(322/773) 1.0                     | 17.7(136/770) 1.0                     |
| Yes                          | 68.0(68/100) 0.61(0.48–0.79)          | 28.3(41/145) 0.65(0.48–0.92)         | 8.8(13/148) 0.53(0.30–0.94)         |

doi:10.1371/journal.pone.0148915.t002
CD4 count < 200 cells/µL. Some studies showed that CD4+ count increased quickly in the first year after treatment, but CD4+ count were not increased significantly in the second or third year. The above studies in CD4+ recovery were not concerned with continuous MVL. According to the EuroSIDA data, in patients starting HAART with lower CD4+ counts (< 200 cells/µL), CD4+ count significantly rose even after 5 years of continuous VL with HAART. Similar to previous studies, the authors found that patients with lower CD4 levels (<100 cells/µL) before treatment, CD4 count still increased after long-term treatment, even at five years. At present, an increase in 150 cells/µL during the first year of HAART is identified as clinical success among patients with CD4+ count more than 100 cells/µL before initial treatment, and for the low CD4+ count (< 100 cells/µL) before initial treatment, the CD4+ count increase is slow. A study in Netherlands showed that CD4+ recovery was worse among patients with CD4+ count below 200 cells/µL, but such trials were not restricted under continuous MVL suppression. This study showed that the median CD4+ count rose approximately 146 cells/µL under the continuous MVL suppression in the first year among the patients with CD4+ count less than 100 cells/µL before starting HAART.

A study from the UK (CHIC) showed that patients with CD4+ T cell count below 100 cells/µL at initial treatment and had maintained continuous VL suppression after treatment, had over 50, 14, and 3% chance of returning to ≥ 200, 350, 500 cells/µL after 1 year of treatment, respectively, and over 90, 59, and 25% after three years of treatment, respectively. Our study, similar to the CHIC study, estimated that the rate of patients CD4+ count recovery to the endpoints (≥ 200, 350, 500 cells/µL) in the first year of HAART was 43.6, 8.6, and 2.5%, respectively, the proportion returning to these endpoints in the third year of treatment was 90.8, 46.3, and 17.9%, respectively. The proportion of patients that recovered to these thresholds in the fifth year of HAART was 97.1, 72.2, and 36.4%, respectively. Our findings suggest that immunological function was constantly improving among patients even at several years after HAART, and that the CD4+ count increased significantly among the patients with the long-term treatment. The study results suggest that patients with severely impaired immune function before treatment should remain in long term HAART.

We found that factors including increasing age, baseline CD4+ count, initial regimens, changes in regimen and whether TMP-SMZ was taken during the treatment were associated with CD4+ T cell count recovery. Previous studies demonstrated that increasing age is a well-recognized protective factor for CD4+ count recovery. A study from Uganda illustrated that the CD4+ count response reduced 1.5 cells/µL per year as patients aged. Data from a study of 4,041 patients showed among patients with HIV-RNA load below 50 copies/ml, the CD4+ count reduced 8.7 cells/µL as patients aged 10 years. Consistent with previous studies, we found that age had an effect in lowering the rate of change in CD4+ count and resulted in incomplete recovery to ≥ 200, 350 cells/µL. This evidence might support the United States Department of Health and Human Services guidelines in 2012 that recommended HAART for all patients over 50 years old, irrespective of CD4+ count. We results suggested that all elderly patients should receive early HAART, in order to rebuild the better immunological function, regardless of CD4+ count.

Similar to another other study, our study found that lower CD4+ count at initial treatment was a risk factor for CD4+ count recovery to ≥ 200 cells/µL, but not associated with CD4+ count recovery to ≥ 350 or 500 cells/µL. It was suggested that in patients with initial CD4+ count below 100 cells/µL, the CD4 count increased significantly in the first year, the higher initiation CD4 count level maybe an issue for CD4 recovery to ≥ 200 cells/µL. But for the CD4 count above 350 or 500 cells/µL, patients need long-term (the median years was 3.33 and 6.91) to recovery, baseline CD4+ level was no longer a factor.
Patients who used EFV for initial regimens had a higher rate of incomplete CD4+ recovery compared to the NVP regimen, while the AZT regimen compared to D4T regimen significantly affected CD4 recovery. Previous studies showed that EFV could produce higher virological suppression rates than NVP, whether the regime contained TDF or AZT [27], which might be influenced by consequence of toxicity and adherence in NVP [28]. There was no difference in the long-term effectiveness of EFV- and NVP-based HAART, however, patients initiating NVP were more likely to develop early toxicity and discontinue this drug [29]. A study which involved 2817 patients from sub-Saharan Africa demonstrated that NVP was risk factor for virological failure (aHR1.52, 95% CI 1.24–1.86) [30]. Data from a cohort study in India illustrated that use of NVP and EFV-based HAART in antiretroviral-naive Indian patients led to significant and durable rise in CD4+ cell count. Although the study was observational and non-randomized, it showed equivalent immunological response amongst NVP and EFV-based HAART [31]. A study in Uganda showed no significant difference in the CD4+ recovery between EFV and NVP after treatment [32]. Data from the HIV-CAUSAL Collaboration indicated that compared with the EFV regimen, the annual change in the CD4+ cell count (95% CI) for the NVP regimen was −11.49 cells/μL (−18.13, −4.86) [33]. In contrast, our study demonstrated that EFV was a risk factor of incomplete CD4+ recovery in patients with lower CD4+ count before treatment. Among patients with long-term virological suppression treatments, the effect of NVP was better than EFV for CD4+ count recovery, without poor compliance and toxicity.

D4T as the first line drug was used in China before 2013. However, severe side effects associated with D4T use, such as peripheral neuropathy, lactic acidosis and lipodystrophy were frequently observed and accumulated over time in several African cohorts [34,35]. A study conducted in South Africa illustrated that the mean of increasing in CD4+ count during the first year of HAART, which included D4T was 90.0 cells/μL (95% CI: 77.6, 102.3), and AZT was 69.0 cells/μL (95% CI: 62.5, 75.4) [36]. A study in Netherlands showed that patients could achieve higher (aHR = 1.30, 95% CI 1.08–1.57) CD4+ recovery with using D4T/3TC compared to AZT/3TC [8]. Our study also found similar results, AZT had higher rate of incomplete CD4+ recovery than D4T in initial regimen.

Ever changing regimen during HAART was associated with the CD4+ count recovery. Some studies suggested first antiretroviral therapy was often switched to simpler, more potent, better-tolerated regimens than the replaced regimen [37,38]. Previous studies demonstrated that side effect of patients who changed regimens during the treatment such as toxicity [39], experienced virological failure and resistance-conferring mutations within the viral genome than the patients who never changed the regimen, mainly reason due to poor compliance [40,41]. Other studies showed that the effect was significant better after changing the regimen, the median CD4+ count increased from 157 cells/μL at baseline to 307 cells/μL in 120 weeks [42]. All previous studies were not involved in the continuous HIV-RNA load MVL suppression. Our study found that patients who had changed their regimen had lower CD4+ recovery compared to those who had never changed regimens. It has been suggested the first line antiretroviral had better effects in patients with lower CD4+ count in long-term continuous virological suppression treatments.

Several studies have demonstrated that cotrimoxazole prophylaxis could protect against opportunistic infections, such as Pneumocystis jirovecii pneumonia, Toxoplasmosis and malaria [43]. A study from China found that cotrimoxazole prophylaxis during HAART reduced 37% mortality in HIV-infected patients [44], other studies showed the similar results [45]. Study from the DART cohort showed that patients who took co-trimoxazole did not have greater CD4+ cell count compared those who never took co-trimoxazole [46], and that cotrimoxazole had no significant effect on CD4+ recovery during long-term treatment. Our study found that patients who had used a co-trimoxazole prophylaxis had significantly lower
CD4+ count recovery compared to those who had never used a cotrimoxazole prophylaxis. However, the small sample size of patients who used cotrimoxazole prophylaxis, such as patients with severely immunocompromised systems, should be taken into consideration.

Several points should be considered. The CD4+ count recovery to the key endpoints (≥ 200, 350, 500 cells/μL) was analyzed while patients achieved MVL suppression (VL < 50 copies/ml) during the treatment, thus increasing the validity of the study. The risk factor analysis of CD4+ count recovery focused on the key thresholds. However, this study has several limitations. We identified all patients with initial CD4+ T count < 100 cells/μL in the analysis, but over half of the patients did not achieve continuous MVL suppression or did not meet other criteria, were excluded. This means that our findings focus on patients with lower CD4+ T cell count in the initial HAART, while achieving continuous MVL suppression by the time of 9 months after treatment. Owing to the side effect of treatment or drug toxicity, D4T was no longer used in China in 2013, and patients who took D4T changed to use AZT or TDF, so consideration should be given to whether TDF might affect the CD4+ count recovery. This was also an observational study therefore patients were not randomly chosen to start initial treatment regimens which were later changed during the course of treatment, as such findings should be interpreted with caution.

In conclusion, this is the first study that examines the CD4+ T cell count recovery in HIV+ patients with lower CD4+ T cell count (< 100 cells/μL) at initial treatment, achieving and maintaining continuous virological suppression by the 9 months after HAART in China. The proportion of patients with initially low CD4 counts after nine months of treatment and that had achieved continuous virological suppression was greater than 70% for persons with CD4+ count ≥ 350. Conversely, only 35% of patients recovered to 500 cells/μL after 5 years of treatment, and continued to significantly rise with long-term HAART. Early HAART intervention will be necessary for achieving effective CD4+ T cell responses and optimal immunological function in HIV+ patients.

Author Contributions

Conceived and designed the experiments: LH XHP ZHD NW ZHP. Performed the experiments: LH XZ JFZ JZY JLZ YX JJ LC. Analyzed the data: LH XHP ZHD PH XZ JMJ NW. Contributed reagents/materials/analysis tools: LH ZHD PH ZHP. Wrote the paper: LH XHP ZHD XZ ZHP NW.

References

1. Zhang F, Dou Z, Ma Y, Zhang Y, Zhao Y, Zhao D, et al. (2011) Effect of earlier initiation of antiretroviral treatment and increased treatment coverage on HIV-related mortality in China: a national observational cohort study. Lancet Infect Dis 11: 516–524. doi: 10.1016/S1473-3099(11)70097-4 PMID: 21600849

2. (2013) Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. Geneva: World Health Organization.

3. Hogg RS, Yip B, Chan KJ, Wood E, Craib KJ, O’Shaughnessy MV, et al. (2001) Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 286: 2568–2577. PMID: 11722271

4. Chadborn TR, Delpech VC, Sabin CA, Sinka K, Evans BG (2006) The late diagnosis and consequent short-term mortality of HIV-infected heterosexuals (England and Wales, 2000–2004). AIDS 20: 2371–2379. PMID: 17117024

5. Engsig FN, Zangerle R, Katsarou O, Dabis F, Reiss P, Gill J, et al. (2014) Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery. Clin Infect Dis 58: 1312–1321. doi: 10.1093/cid/ciu038 PMID: 24457342

6. Mocroft A, Phillips AN, Ledergerber B, Katlama C, Chiesi A, Goebel FD, et al. (2006) Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia. AIDS 20: 1141–1150. PMID: 16691065
7. Althoff KN, Justice AC, Gange SJ, Deeks SG, Saag MS, Silverberg MJ, et al. (2010) Virologic and immunologic response to HAART, by age and regimen class. AIDS 24: 2469–2479. doi: 10.1097/QAD.0b013e32833ed14 PMID: 20829678
8. Smit M, Smit C, Geerlings S, Gras L, Brinkman K, Hallett TB, et al. (2013) Changes in first-line CART regimens and short-term clinical outcome between 1996 and 2010 in The Netherlands. PLoS One 8: e76071. doi: 10.1371/journal.pone.0076071 PMID: 24098764
9. Mocroft A, Phillips AN, Gatell J, Ledergerber B, Fisher M, Clumeck N, et al. (2007) Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study. Lancet 370: 407–413. PMID: 17659333
10. O’Connor JL, Smith CJ, Lampe FC, Hill T, Gompels M, Hay P, et al. (2014) Failure to achieve a CD4+ cell count response on combination antiretroviral therapy despite consistent viral load suppression. AIDS 28: 919–924. doi: 10.1097/QAD.0000000000000165 PMID: 24335482
11. Moore RD, Keruly JC (2007) CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis 44: 441–446. PMID: 17205456
12. (2015) Update on the AIDS/STD epidemic in China and main response in control and prevention in December, 2014. Chinese Journal of AIDS & STD: 87.
13. Tang H, Mao Y, Shi CX, Han J, Wang L, Xu J, et al. (2014) Baseline CD4 cell counts of newly diagnosed HIV cases in China: 2006–2012. PLoS One 9: e96098. doi: 10.1371/journal.pone.0096098 PMID: 24901790
14. Wu Z, Sullivan SG, Wang Y, Rotheram-Borus MJ, Detels R (2007) Evolution of China's response to HIV/AIDS. Lancet 369: 679–690. PMID: 17321313
15. Ma Y, Zhao D, Yu L, Bulterys M, Robinson ML, Zhao Y, et al. (2010) Predictors of virologic failure in HIV-1-infected adults receiving first-line antiretroviral therapy in 8 provinces in China. Clin Infect Dis 50: 264–271. doi: 10.1086/649215 PMID: 20017637
16. Kaufmann GR, Perrin L, Pantaleo G, Opravil M, Furrer H, Telenti A, et al. (2003) CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Intern Med 163: 2187–2195. PMID: 14557216
17. Kaufmann GR, Furrer H, Ledergerber B, Perrin L, Opravil M, Vernazza P, et al. (2005) Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin Infect Dis 41: 361–372. PMID: 16007534
18. Valdez H, Connick E, Smith KY, Lederman MM, Bosch RJ, Kim RS, et al. (2002) Limited immune restoration after 3 years’ suppression of HIV-1 replication in patients with moderately advanced disease. AIDS 16: 1859–1866. PMID: 12351945
19. (2012) China free ART manual. Beijing: Chinese Center for Disease Control and Prevention.
20. Smit M, Smit C, Geerlings S, Gras L, Brinkman K, Hallett TB, et al. (2013) Changes in first-line CART regimens and short-term clinical outcome between 1996 and 2010 in The Netherlands. PLoS One 8: e76071. doi: 10.1371/journal.pone.0076071 PMID: 24098764
21. Mutevedzi PC, Lessels RJ, Rodger AJ, Newell ML, (2011) Association of age with mortality and virological and immunological response to antiretroviral therapy in rural South African adults. PLoS One 6: e21795. doi: 10.1371/journal.pone.0021795 PMID: 21747959
22. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, et al. (2002) Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 360: 119–129. PMID: 12126821
23. Viard JP, Mocroft A, Chiesi A, Kirk O, Roge B, Panos G, et al. (2001) Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study. J Infect Dis 183: 1290–1294. PMID: 11262215
24. Kaufmann GR, Bloch M, Finlayson R, Zaunders J, Smith D, Cooper DA (2002) The extent of HIV-1-related immunodeficiency and age predict the long-term CD4 T lymphocyte response to potent antiretroviral therapy. AIDS 16: 359–367. PMID: 11834947
25. Crawford KW, Wakabi S, Magala F, Kibuuka H, Liu M, Hamme TE (2015) Evaluation of treatment outcomes for patients on first-line regimens in US President's Emergency Plan for AIDS Relief (PEPFAR) clinics in Uganda: predictors of virological and immunological response from RV288 analyses. HIV Med 16: 95–104. doi: 10.1111/hiv.12177 PMID: 25124078
26. Moore RD, Keruly JC (2007) CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis 44: 441–446. PMID: 17205456
27. Amoroso A, Elfienne-Mesubi M, Edozien A, Ojo O, Sheneberger R, Obiefune M, et al. (2012) Treatment outcomes of recommended first-line antiretroviral regimens in resource-limited clinics. J Acquir Immune Defic Syndr 60: 314–320. doi: 10.1097/QAI.0b013e31824e5256 PMID: 22343178
28. Gandhi M, Benet LZ, Bacchetti P, Kalinowski A, Anastos K, Wolfe AR, et al. (2009) Nonnucleoside reverse transcriptase inhibitor pharmacokinetics in a large unselected cohort of HIV-infected women. J Acquir Immune Defic Syndr 50: 482–491. PMID: 19408353

29. Sarfo FS, Sarfo MA, Kasim A, Phillips R, Booth M, Chadwick D (2014) Long-term effectiveness of first-line non-nucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral therapy in Ghana. J Antimicrob Chemother 69: 254–261. doi: 10.1093/jac/dkt336 PMID: 24003181

30. Nachega JB, Hislop M, Dowdy DW, Gallant JE, Chaisson RE, Regensberg L, et al. (2008) Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults. AIDS 22: 2117–2125. doi: 10.1097/QAD.0b013e32834074f7 PMID: 18823875

31. Patel AK, Pujari S, Patel K, Patel J, Shah N, Patel B, et al. (2006) Nevirapine versus efavirenz based antiretroviral treatment in naive Indian patients: comparison of effectiveness in clinical cohort. J Assoc Physicians India 54: 915–918. PMID: 17334006

32. Crawford KW, Wakabi S, Magala F, Kibuuka H, Liu M, Hamme TE (2015) Evaluation of treatment outcomes for patients on first-line regimens in US President's Emergency Plan for AIDS Relief (PEPFAR) clinics in Uganda: predictors of virological and immunological response from RV88 analyses. HIV Med 16: 95–104. doi: 10.1111/hiv.12177 PMID: 25124078

33. Cain LE, Phillips A, Lod S, Sabin C, Bansli L, Justice A, et al. (2012) The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study. AIDS 26: 1691–1705. PMID: 22546987

34. van Oosterhout JJ, Mallewa J, Kaunda S, Chagoma N, Njalale Y, Kampira E, et al. (2012) Stavudine toxicity in adult longer-term ART patients in Blantyre, Malawi. PLoS One 7: e42029. doi: 10.1371/journal.pone.0042029 PMID: 22848696

35. Forna F, Liechty CA, Solberg P, Asiiemwe F, Were W, Mermin J, et al. (2007) Clinical efficacy of highly active antiretroviral therapy in a home-based AIDS care program in rural Uganda. J Acquir Immune Defic Syndr 44: 456–462. PMID: 17279048

36. Velen K, Lewis JJ, Charalamous S, Grant AD, Churchyard GJ, Hoffmann CJ (2013) Comparison of tenofovir, zidovudine, or stavudine as part of first-line antiretroviral therapy in a resource-limited-setting: a cohort study. PLoS One 8: e64459. doi: 10.1371/journal.pone.0064459 PMID: 23691224

37. Haering M, Hordt A, Meyer-Hermann M, Hernandez-Vargas EA (2014) Computational study to determine when to initiate and alternate therapy in HIV infection. Biomed Res Int 2014: 472869. doi: 10.1155/2014/472869 PMID: 24900966

38. Lee FJ, Amin J, Carr A (2014) Efficacy of initial antiretroviral therapy for HIV-1 infection in adults: a systematic review and meta-analysis of 114 studies with up to 144 weeks' follow-up. PLoS One 9: e97482. doi: 10.1371/journal.pone.0097482 PMId: 22848696

39. Moniz P, Alcada F, Peres S, Borges F, Baptista T, Miranda AC, et al. (2014) Nuke-sparing regimens as a main simplification strategy and high level of toxicity resolution after antiretroviral switch: the SWITCHART Study. J Int AIDS Soc 17: 19819. doi: 10.7448/IAS.17.4.19797 PMID: 25397541

40. Carrero-Gras A, Antela A, Munoz-Rodriguez J, Diaz-Menendez M, Viciana P, Torrella-Domingo A, et al. (2014) Nuke-sparing regimens as a main simplification strategy and high level of toxicity resolution after antiretroviral switch: the SWITCHART Study. J Int AIDS Soc 17: 19819. doi: 10.7448/IAS.17.4.19819 PMID: 25397563

41. (2010) Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approach: 2010 Revision. Geneva: World Health Organization.

42. Han Y, Li Y, Xie J, Qiu Z, Li Y, Song X, et al. (2015) Week 120 Efficacy of Tenofovir, Lamivudine and Emtricitabine in Tenofovir- and Efavirenz-Containing Regimens Among Treatment-Experienced HIV Patients. PLoS One 10: e120705.

43. Mermin J, Lule J, Ekwaru JP, Malamba S, Downing R, Ransom R, et al. (2004) Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet 364: 1428–1434. PMID: 15488218

44. Cheng W, Wu Y, Wen Y, Ma Y, Zhao D, Dou Z, et al. (2015) Cotrimoxazole prophylaxis and antiretroviral therapy: an observational cohort study in China. Bull World Health Organ 93: 152–160. doi: 10.2471/BLT.14.142745 PMID: 25838611

45. Chinu C, Bhat GJ, Walker AS, Mulenga V, Sinyinza F, Lishimpi K, et al. (2004) Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial. Lancet 364: 1865–1871. PMID: 15555666

46. Walker AS, Ford D, Glikas CF, Munderi P, Ssali F, Reid A, et al. (2010) Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort. Lancet 375: 1278–1286. doi: 10.1016/S0140-6736 (10)60057-8 PMID: 20347483